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Background:Neck Pain (NP) has been ranked as one of the top chronic pain conditions in terms of prevalence and years lived with
disability in the latest Global Burden of Disease. NP has remarkable socio-economic consequences however, research efforts are limited.
Discrepancies among guidelines recommendations on management of chronic neck pain exist. The purpose of this study protocol is to
provide the methods for a review with network meta-analysis to identify the most effective interventions for chronic neck pain.
Methods: The following databases will be searched from their inception to February 2019: Cochrane Controlled Trials Register
(CENTRAL), PubMed, CINAHL, Scopus, ISI Web of Science and PEDro.
Randomized controlled trials (RCTs) on pharmacological and not pharmacological interventions will be included and their risk of
bias will be evaluated using the Cochrane Risk of bias tool. Primary outcomes will be reduction in pain and disability. A network meta-
analysis will be carried out and pairwise meta-analysis will be conducted using Stata 15 software. Grading of recommendations
assessment, development, and evaluation (GRADE) will be applied to assess quality of the body of the evidence.
Results: The results of this review will be submitted to a peer-review journal for publication.
Conclusion:This networkmeta-analysis will provide a comprehensive review on themost effective treatments for themanagement
of chronic neck pain providing key evidence-based information to patients, clinicians and other relevant stakeholders.Registration:
PROSPERO (registration number CRD42019124501).
Abbreviations: GRADE = grading of recommendations assessment, development, and evaluation, NMA = network meta-
analysis, NP = neck pain, NSAIDs = non-steroidal anti-inﬂammatory drugs , RCT = randomized controlled trial.
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11. Introduction
Neck pain (NP) is listed among the worldwide leading causes for
Years Lived with Disability according to the latest Global Burden
of Disease 2017.[1,2] NP has an annual prevalence ranging
between 15% and 50%, being greater in females with the highest
peaks in middle age.[3] It has a multifactorial and complex
etiology: it might be related to ergonomic or individual factors
such as age, behavioral attitude or psychosocial distress such as
anxiety or job satisfaction.[4] The most common NP form is the
non-speciﬁc which denotes pain not attributable to a speciﬁc
cause. Usually, it is classiﬁed according to the duration of
symptom into acute, when pain lasts less than 6 weeks, subacute
when pain lasts up to three months or chronic when symptoms
persist more than 3 months. Even though acute NP mostly
resolves spontaneously (probably due to its natural course),
nearly half of the patients will develop a chronic condition
characterized by constant pain or frequent occurrences.[5] The
transition from acute to chronic is often related to biological,
psychosocial, and occupational factors.[6,7] Themore persistent is
the pain, the less favorable is its prognosis.[8]
The social and economic burden of NP is surely recognized[9]:
quality of life, mood, ability to cope, social participation,
employment rates and job income are reduced and inﬂuenced by
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relevant consequences on productive capacity and sick leave,
leading to high attributable costs.[10] For instance, in the United
States, costs in management for NP are estimated to be as high as
$86 billion a year.[11] Thus, it becomes fundamental to identify
the most effective treatments for patient with chronic NP to
reduce pain and disability.
Despite its known burden on families, communities, healthcare
systems, and companies, NP has received very little attention in
terms of research efforts, that is, 0.12 trials per million disability
adjusted life years with a total of 30million disability adjusted life
years globally.[12] Indeed, few large randomized clinical trials
have focused merely on NP and evidence on how to manage this
condition is often extrapolated from trials with mixed popula-
tions (e.g., spinal pain, chronic pain in general). Therefore, while
several pharmacological and non-pharmacological intervention
exist for the management of patients with chronic NP, there are
discrepancies among guidelines recommendations: the most
conﬂicting recommendations concern interventions such as
electrotherapy, traction, laser therapy, acupuncture, heat/cold,
and medications.[13]
Themajority of the published clinical trials on the management
of NP provide head-to-head comparisons of 2 interventions.
Nevertheless, traditional pairwise meta-analyses are not able to
integrate all the evidence from different studies with different
comparisons. Recent methodological innovations from network
meta-analysis (NMA) allow having a wider picture on effective
interventions for a health condition by pooling results from
individual studies and providing a multiple comparison evidence
synthesis.
1.1. Aim
The goal of this study is to assess the effectiveness of currently
available pharmacological and non-pharmacological interven-
tions for patients with chronic non-speciﬁc NP. Moreover, the
effectiveness of treatments for chronic NP will be ranked in
respect to the likelihood to be the best among all the available
treatments. To meet this goal, a comprehensive systematic review
with a multiple comparison network meta-analysis will be
performed. This review will shed light on the most effective
treatments providing key evidence-based information to patients,
clinicians and other relevant stakeholders (e.g., policy makers).2. Methods
2.1. Protocol register
This systematic review protocol follows the Preferred Reporting
Items for Systematic Review and Meta-Analyses Protocol
(PRISMA-P) guidelines and its extension, PRISMA-NMA
extension statement to compile network meta-analysis con-
tents.[14]We have completed the PRISMA-P checklist (Additional
ﬁle 1). Our protocol has been registered in the PROSPERO
database (PROSPERO 2019 CRD42019124501. Available
from: http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42019124501).2.2. Ethics
No ethical approval is needed since all the clinical studies included
were approved by ethical committees and institutional review
boards besides, patients signed a written informed consent.22.3. Information sources and search strategies
We will search the following electronic databases from their
inception to February 2019: Cochrane Controlled Trials Register
(CENTRAL), PubMed (Medline), CINAHL, Scopus, ISI Web of
Science and PEDro. The PubMed (Medline) search strategy,
included in Appendix 1, http://links.lww.com/MD/D159, will be
adopted and adapted in the other databases. Handmanual search
on non-indexed journal for further references will be performed.
References list of all eligible studies and any systematic reviews
and meta-analysis will also be checked during the search process.
No restrictions regarding year of publication and languagewill be
applied. In case of studies for which the English translation could
not be made they will be classiﬁed as awaiting assessment.3. Eligibility criteria
3.1. Study design
We will include only randomized controlled trials (RCT). Quasi-
randomized trials and cross-over trials will be excluded.3.2. Participants
We will include studies presented as full-text articles on adults
(over 18 years old) with chronic non-speciﬁc NP. To be
considered chronic, the pain should last for a minimum of
3 months duration at the time of intervention[15] or, in the
absence of this explicit description, when the authors themselves
will deﬁne the pain as “chronic”. Consistent with the deﬁnition of
non-speciﬁc NP, we will exclude studies including patients with(i) speciﬁc diagnoses such as radicular pain, radiculopathy,
myelopathy, fracture, infection, dystonia, tumor, inﬂamma-
tory disease, and osteoporosis, and(ii) subgroups of population (e.g., pregnant women). Studies
focusing on whiplash-associated disorders or ﬁbromyalgia
will also be excluded as well as studies on mixed pain
populations (e.g., spinal pain both from neck and back)
where results for patients with NP are not presented
separately.
3.3. Interventions
We will include single conservative intervention irrespective of
modality (pharmacological and non-pharmacological), frequen-
cy or intensity, and treatment extent. We will include
pharmacological interventions such as, for example, paraceta-
mol, steroids, non-steroidal anti-inﬂammatory drugs (NSAIDs)
or opioids; and non-pharmacological interventions like manual
therapy, exercise therapy and so forth. We will exclude studies if
the intervention will be surgical or an alternative form of medical
treatments (e.g., homeopathy, herbal medicine).
Maximum 2 combined treatments will be considered as unique
node according to a usual clinical practice (e.g., manual therapy
plus exercise, manual therapy plus physical therapies, physical
therapies plus exercise, exercise plus education).[16] Since one of
the major issues for non-pharmacological treatments is to gather
a homogenous group for allowing comparisons, we will
transparently justify the node-making process a posteriori once
we obtain the eligible studies and assess the amount of
information.[17] However, a potential list of treatment involved
in the nodes is reported in Figure 1.
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The primary outcomes of interest will be(i)Figu
Stre
[c]:pain intensity measured, for example, with a Numeric Rating
Scale (NRS) or a Visual Analogue Scale (VAS) and(ii) physical functioning, that is, disability, measured, for
example, with the Neck Disability Index (NDI) or the Neck
Bournemouth Questionnaire (NBQ). These 2 outcomes have
been consistently recommended as core outcome domains for
clinical trials in patients with spinal pain.[18,19] As secondary
outcome we will report adverse events. We will gather
information at the following time point: short-term (closest to
1 month assessment), intermediate (closest to 3–6 months)
and long-term follow-up (closest to 12months). For example,
if a treatment lasted 3 weeks and the trial considers 1 week
and 4 weeks of follow-up, we would select the 4 weeks as
short term of point assessment.
3.5. Study selection
The list of abstract and title obtained by the searches will be
screened according to inclusion and exclusion criteria by two
independent authors. Then, the same 2 independent authors will
assess full texts if potentially eligible. In case of disagreements, we
will resolve through discussion or consulting a third author.
Reasons for exclusion of full-texts will be monitored. We
used Endnote (www.endnote.com) and Rayyan QCRI (REF
https://rayyan.qcri.org/welcome) to manage the study selection
phase.re 1. Network graph. Exercise [a]: Motor Control, Free and Supervised e
tching. Manual Therapy [a]: Myofascial techniques, Trigger point treatment, So
Passive mobilization, Mobilization-with-Movement.
33.6. Data extraction
We will use a pre-deﬁned data extraction form within an Excel
spreadsheet to gather the data form the included studies. Two
authors will independently extract data about general character-
istics and outcomes of interest from the included studies. Any
disagreements will be solved via discussion with another member
of the reviewing team.
We will extract the following general characteristics from each
RCT: name of ﬁrst author and country, year of publication,
setting, number of centers, population characteristics (e.g., age,
sex, pain duration), number of participants, dropouts, type of
experimental and control intervention with details (e.g., length of
treatment, frequency), primary and secondary outcomes’ meas-
urements, signs of central sensitization. The outcome measures of
interest will be gathered at post-treatment assessment. If any data
from baseline and post treatment will not be available, we will
contact the corresponding authors. In case of no response,
missing values will be imputed from all outcome data as last
option.[20] Intention-to-treat analysis data will be used whenever
available.3.7. Risk of bias assessment
Risk of bias in RCTs will be assessed by Cochrane Collabo-
ration’s risk of bias tool (modiﬁed version by the Cochrane Back
& Neck).[21] Two authors will independently assess the domains
as “low”, “high” or ‘unclear’ risk of bias if any information is
reported. A summary ‘Risk of bias’ table will be incorporated into
the interpretations of results. Any disagreements will be resolvedxercise; Exercise [b]: Strength and Endurance Training; Exercise [c]:Muscle
ft-tissue-techniques; Manual Therapy [b]: HVLA/Manipulation; Manual Therapy
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author will be consulted and a decision made.4. Data synthesis
4.1. Description of the available data
We will present the available direct evidence between different
treatments performing a network diagram. We will evaluate the
feasibility and the clinical relevance of the network graphically
through the diagram and looking at(i) the number of comparisons in the network with available
direct data;(ii) the presence of direct evidence based on single studies;
(iii) the presence of “closed loop”; and
(iv) whether any relevant treatment is not represented in the
network.4.2. Standard pairwise meta-analyses and network meta-
analyses
We will perform a pairwise meta-analysis with at least 2 studies
for each primary outcome using a random-effects model for each
direct contrast.[22] The I2 statistic will be used to explore between-
study statistical heterogeneity within each head to head
comparisons: I2 value of 25% to 49% will indicate low degree
of heterogeneity, 50% to 75% moderate degree of heterogeneity
and more than 75% high degree of heterogeneity.[23] We will run
these analyses using Review Manager 5.3 software.[24]
A network meta-analysis within a frequentist setting will be
performed using all the available evidence. We will assume equal
heterogeneity across all treatment comparisons, and accounting
for correlations induced by multi-arm studies.[25,26] We will use a
multivariate normal model with random-effects [27,28] presenting
all possible summary relative effect size for each outcome in a
league table. We will also estimate the relative ranking of the
effectiveness of pharmacological and non-pharmacological
interventions through the distribution of the ranking probabili-
ties and the surface under the cumulative ranking curves
(SUCRAs). We will make use of Stata 15 software for the
hereby described analyses, in particular we will use the ‘network’
package and results will be displayed with the network graph
package.[29–31]4.3. Assumption of transitivity
Transitivity is a fundamental assumption beyond the validity of
indirect comparisons and, therefore, of the entire network meta-
analysis. Thus, we will assume that any patient that meets the
inclusion criteria is “jointly randomizable” to any of the eligible
pharmacological and non-pharmacological treatment for NP in
the network. We will assess the transitivity by looking at possible
effect modiﬁers (clinical and methodological features) across the
head-to-head comparisons.4.4. Assessment of inconsistency
Consistency is the statistical manifestation of transitivity. We will
evaluate inconsistency in the entire network using the design-by-
treatment interaction model based on x2 test as described by
Higgins et al.[27] Then, we will look at local inconsistency in each4closed loop using the loop-speciﬁc approach, which denotes the
difference between direct and indirect estimates for a speciﬁc
comparison (inconsistency factor). A node-splitting function will
be also performed to separate trial-level evidence for a particular
comparison (or node) to compare consistency from direct
evidence (i.e., head-to-head trials from pairwise meta-analysis)
versus indirect evidence (i.e., from network meta-analysis).4.5. Subgroup and sensitivity analyses
If important heterogeneity and inconsistency are detected, wewill
explore the possible sources performing subgroup analysis.4.6. GRADE quality assessment
We will use the Grades of Recommendation, Assessment,
Development and Evaluation (GRADE) approach to evaluate
the quality of the body of evidence contributed to the
network.[32,33] We will appraise the GRADE domains (study
limitations, indirectness, inconsistency, imprecision and publica-
tion bias). The framework combines judgments about direct and
indirect, providing an assessment of reliability of NMA treatment
effects.5. Discussion, ethics and dissemination
NP is one of the most burdensome musculoskeletal disorders in
the adult population. Given its social and economic impact, it is
urgent to ﬁnd the most effective pharmacological or conservative
treatments to reduce pain and improve physical functioning in
people suffering from this condition. This systematic review is the
ﬁrst effort to compare direct and indirect effects of different
conservative approaches in the management of patients with
chronic NP. The results will have a direct positive impact on the
development of future guidelines and on the clinical decision
making process in treatment prescription. We will adopt
strategies to disseminate our results to ensure the successful
uptake of this research project, including peer-reviewed pub-
lications, conference presentations, dissemination to local,
national, and international policy-makers.Author contributions
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